DK1425277T3 - Urinstof-forbindelser aktive som vanilloid-receptor-antagonister til behandling af smerte - Google Patents

Urinstof-forbindelser aktive som vanilloid-receptor-antagonister til behandling af smerte

Info

Publication number
DK1425277T3
DK1425277T3 DK02765023T DK02765023T DK1425277T3 DK 1425277 T3 DK1425277 T3 DK 1425277T3 DK 02765023 T DK02765023 T DK 02765023T DK 02765023 T DK02765023 T DK 02765023T DK 1425277 T3 DK1425277 T3 DK 1425277T3
Authority
DK
Denmark
Prior art keywords
receptor antagonists
urea compounds
treat pain
vanilloid receptor
compounds active
Prior art date
Application number
DK02765023T
Other languages
Danish (da)
English (en)
Inventor
Harshad Kantilal Rami
Mervyn Thompson
Paul Adrian Wyman
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0122156A external-priority patent/GB0122156D0/en
Priority claimed from GB0130547A external-priority patent/GB0130547D0/en
Priority claimed from GB0130503A external-priority patent/GB0130503D0/en
Priority claimed from GB0130505A external-priority patent/GB0130505D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Application granted granted Critical
Publication of DK1425277T3 publication Critical patent/DK1425277T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
DK02765023T 2001-09-13 2002-09-13 Urinstof-forbindelser aktive som vanilloid-receptor-antagonister til behandling af smerte DK1425277T3 (da)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0122156A GB0122156D0 (en) 2001-09-13 2001-09-13 Novel compounds
GB0130547A GB0130547D0 (en) 2001-12-20 2001-12-20 Novel compounds
GB0130503A GB0130503D0 (en) 2001-12-20 2001-12-20 Novel compounds
GB0130505A GB0130505D0 (en) 2001-12-20 2001-12-20 Novel compounds
PCT/GB2002/004206 WO2003022809A2 (en) 2001-09-13 2002-09-13 Urea-compounds active as vanilloid receptor antagonists for the treatment of pain

Publications (1)

Publication Number Publication Date
DK1425277T3 true DK1425277T3 (da) 2009-03-16

Family

ID=27447989

Family Applications (1)

Application Number Title Priority Date Filing Date
DK02765023T DK1425277T3 (da) 2001-09-13 2002-09-13 Urinstof-forbindelser aktive som vanilloid-receptor-antagonister til behandling af smerte

Country Status (32)

Country Link
US (1) US8063078B2 (sl)
EP (3) EP2036902A3 (sl)
JP (2) JP4463552B2 (sl)
KR (3) KR101063679B1 (sl)
CN (1) CN1247568C (sl)
AP (1) AP1818A (sl)
AR (1) AR038786A1 (sl)
AT (1) ATE420083T1 (sl)
AU (1) AU2002329397B2 (sl)
BR (1) BR0212468A (sl)
CA (1) CA2458632C (sl)
CY (1) CY1109449T1 (sl)
DE (1) DE60230773D1 (sl)
DK (1) DK1425277T3 (sl)
EA (1) EA007731B1 (sl)
ES (1) ES2316607T3 (sl)
HK (1) HK1066534A1 (sl)
HU (1) HUP0401923A3 (sl)
IL (2) IL160755A0 (sl)
MA (1) MA26216A1 (sl)
MX (1) MXPA04002379A (sl)
MY (1) MY138086A (sl)
NO (3) NO327009B1 (sl)
NZ (1) NZ531137A (sl)
OA (1) OA12659A (sl)
PE (1) PE20030417A1 (sl)
PL (1) PL213639B1 (sl)
PT (1) PT1425277E (sl)
SI (1) SI1425277T1 (sl)
TW (1) TWI283665B (sl)
UY (1) UY27446A1 (sl)
WO (1) WO2003022809A2 (sl)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY138086A (en) 2001-09-13 2009-04-30 Smithkline Beecham Plc Novel urea derivative as vanilloid receptor-1 antagonist
PT1472225E (pt) 2002-02-01 2010-07-30 Euro Celtique Sa 2-piperazina-piridinas uteis para tratar a dor
DE60325834D1 (de) * 2002-02-20 2009-03-05 Abbott Lab Kondensierte azabicyclischeverbindungen als inhibitoren des vanilloid-rezeptors 1 (vr1)
US7074805B2 (en) 2002-02-20 2006-07-11 Abbott Laboratories Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
US6974818B2 (en) 2002-03-01 2005-12-13 Euro-Celtique S.A. 1,2,5-thiadiazol-3-YL-piperazine therapeutic agents useful for treating pain
EP1556354B1 (en) 2002-06-28 2008-01-23 Euro-Celtique S.A. Therapeutic piperazine derivates useful for treating pain
US7262194B2 (en) 2002-07-26 2007-08-28 Euro-Celtique S.A. Therapeutic agents useful for treating pain
GB0221157D0 (en) * 2002-09-12 2002-10-23 Glaxo Group Ltd Novel treatment
WO2004024710A1 (en) * 2002-09-13 2004-03-25 Glaxo Group Limited Urea compounds active as vanilloid receptor antagonists for the treatment of pain
US7157462B2 (en) 2002-09-24 2007-01-02 Euro-Celtique S.A. Therapeutic agents useful for treating pain
CA2508618C (en) 2002-12-06 2012-02-21 Bayer Healthcare Ag Tetrahydro-naphthalene derivatives
GB0229808D0 (en) * 2002-12-20 2003-01-29 Glaxo Group Ltd Novel compositions
US6933311B2 (en) * 2003-02-11 2005-08-23 Abbott Laboratories Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
JP2006519826A (ja) 2003-03-06 2006-08-31 グラクソ　グループ　リミテッド 疼痛治療のための複素環式尿素誘導体
EP1601665A2 (en) 2003-03-07 2005-12-07 Glaxo Group Limited Urea derivatives
GB0305426D0 (en) 2003-03-08 2003-04-16 Glaxo Group Ltd Novel compounds
SE0301446D0 (sv) 2003-05-16 2003-05-16 Astrazeneca Ab New Compounds
ATE556067T1 (de) 2003-05-20 2012-05-15 Ajinomoto Kk Modulatoren des vanilloid rezeptors
EP1493438A1 (en) * 2003-07-03 2005-01-05 Bayer HealthCare AG Vanilloid receptor (VR) inhibitors for treatment of Human Immunodeficiency Virus (HIV)-mediated pain states
GB0319151D0 (en) * 2003-08-14 2003-09-17 Glaxo Group Ltd Novel compounds
GB0319150D0 (en) 2003-08-14 2003-09-17 Glaxo Group Ltd Novel compounds
JP4833069B2 (ja) * 2003-10-01 2011-12-07 ゼンション・リミテッド テトラヒドロ−ナフタレンおよび尿素誘導体
EP1679296A4 (en) 2003-10-14 2007-12-26 Ajinomoto Kk DERIVE ETHERE
JP2007509846A (ja) * 2003-10-15 2007-04-19 バイエル・ヘルスケア・アクチェンゲゼルシャフト テトラヒドロ−ナフタレンおよび尿素誘導体
CA2545109A1 (en) 2003-11-08 2005-05-19 Bayer Healthcare Ag Tetrahydro-quinolinylurea derivatives
EP1736465A4 (en) 2004-03-31 2009-06-17 Ajinomoto Kk ANILINE DERIVATIVES
WO2006002361A2 (en) 2004-06-24 2006-01-05 Incyte Corporation 2-methylpropanamides and their use as pharmaceuticals
WO2006007851A2 (en) 2004-07-19 2006-01-26 Novo Nordisk A/S Capsaicin inhibitors for treating obesity and-related disorders
KR20060087386A (ko) 2005-01-28 2006-08-02 주식회사 대웅제약 신규 벤조이미다졸 유도체 및 이를 함유하는 약제학적조성물
WO2006098554A1 (en) * 2005-03-16 2006-09-21 Amorepacific Corporation Novel compounds, isomer thereof or pharmaceutically acceptable salts thereof as vanilloid receptor antagonist; and a pharmaceutical composition containing the same
WO2007046867A2 (en) * 2005-05-19 2007-04-26 Xenon Pharmaceuticals Inc. Piperidine derivatives and their uses as therapeutic agents
UY30048A1 (es) 2005-12-23 2007-07-31 Astrazeneca Ab Derivados sustituidos de la n,2-(1h-benzimidazol-1-il) acetamida, composiciones farmacéuticas conteniéndolos, procesos de preparación y aplicaciones
EP1889830A1 (en) * 2006-07-10 2008-02-20 Pharmeste S.r.l. Biarylcarboxyarylamides as vanilloid-1 receptor modulators
EP1882687A1 (en) * 2006-07-27 2008-01-30 Amorepacific Corporation Heterocyclic compounds useful as vanilloid receptor antagonists and pharmaceutical compositions containing the same
JP5254228B2 (ja) * 2006-07-27 2013-08-07 株式會社アモーレパシフィック バニロイド受容体アンタゴニストとしての、新規化合物、その異性体またはその薬学的に許容される塩；並びにそれを含む医薬組成物
TWI433839B (zh) 2006-08-11 2014-04-11 Neomed Inst 新穎的苯并咪唑衍生物290
MX2009002018A (es) 2006-08-25 2009-03-05 Abbott Lab Derivados de indazol que inhiben vanilloide-1 potencial de receptor pasajero (trpv1) y usos de los mismos.
EP2134678A2 (en) 2006-12-20 2009-12-23 Abbott Laboratories N-(5, 6, 7, 8-tetrahydronaphthalen-1-yl) urea derivatives and related compounds as trpv1 vanilloid receptor antagonists for the treatment of pain
EP2323989A4 (en) 2008-03-20 2011-06-22 Abbott Lab METHODS FOR PREPARING AGENTS FOR THE CENTRAL NERVOUS SYSTEM THAT ARE TRPV1 ANTAGONISTS
CN101983197B (zh) 2008-04-18 2015-04-22 大熊制药株式会社 新型苯并噁嗪苯并咪唑衍生物、含有该衍生物的药物组合物及其用途
KR101409651B1 (ko) 2008-05-07 2014-06-18 다이닛본 스미토모 세이야꾸 가부시끼가이샤 시클릭 아민-1-카르복실산 에스테르 유도체 및 그것을 함유하는 약제학적 조성물
WO2010026128A1 (en) * 2008-09-02 2010-03-11 Glaxo Group Limited N-(3-methyl-5-isoquinolinyl)-n'-((3r)-1-[5-(trifluoromethyl)-2-pyridinyl]-3-pyrrolidinyl) urea for the treatment of rhinitis
WO2010026129A1 (en) * 2008-09-02 2010-03-11 Glaxo Group Limited The trpvl antagonist sb-705498 for treating rhinitis
JP2013028536A (ja) * 2009-11-11 2013-02-07 Dainippon Sumitomo Pharma Co Ltd 環状アミン−１−カルボン酸エステル誘導体およびそれを含有する医薬組成物
WO2012045729A1 (en) 2010-10-05 2012-04-12 Glaxo Group Limited Imidazo [1, 2 -a] pyridine and pyrazolo [1, 5 -a] pyridine derivatives as trpv1 antagonists
KR101293384B1 (ko) 2010-10-13 2013-08-05 주식회사 대웅제약 신규 피리딜 벤조옥사진 유도체, 이를 포함하는 약학 조성물 및 이의 용도
WO2012072512A1 (en) 2010-11-29 2012-06-07 Glaxo Group Limited N-cyclobutyl-imidazopyridine or -pyrazolopyridine carboxamides as trpv1 antagonists
GB201101517D0 (en) * 2011-01-28 2011-03-16 Proximagen Ltd Receptor antagonists
WO2012139963A1 (en) 2011-04-11 2012-10-18 Glaxo Group Limited N- cyclobutyl - imidazopyridine - methylamine as trpv1 antagonists
DE102022104759A1 (de) 2022-02-28 2023-08-31 SCi Kontor GmbH Co-Kristall-Screening Verfahren, insbesondere zur Herstellung von Co-Kristallen

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3424761A (en) * 1966-03-07 1969-01-28 Robins Co Inc A H 3-ureidopyrrolidines
US3424760A (en) * 1966-03-07 1969-01-28 Robins Co Inc A H 3-ureidopyrrolidines
GB1460389A (en) * 1974-07-25 1977-01-06 Pfizer Ltd 4-substituted quinazoline cardiac stimulants
DE68918991T2 (de) 1988-06-17 1995-04-27 Procter & Gamble Anwendung von Vanillin-Derivaten zur Herstellung eines Arzneimittels zur Behandlung von Herpes simplex-Infektion.
HU206082B (en) 1988-12-23 1992-08-28 Sandoz Ag Process for producing capsaicin derivatives and pharmaceutical compositions comprising such compounds
CA2017383A1 (en) 1989-06-08 1990-12-08 Raymond R. Martodam Use of vanilloids for the treatment of respiratory diseases or disorders
WO1992009285A1 (en) 1990-11-27 1992-06-11 The Procter & Gamble Company Combinations of vanilloid compounds and phosphonate antiviral compounds for treatment of herpes infections
US5149704A (en) 1991-05-03 1992-09-22 Abbott Laboratories Platelet activating antagonists
CA2197364A1 (en) * 1996-02-15 1997-08-16 Toshikazu Suzuki Phenol compound and process for preparing the same
AU8270898A (en) * 1997-06-26 1999-01-19 Eli Lilly And Company Antithrombotic agents
EP1019045B1 (en) * 1997-06-26 2005-06-08 Eli Lilly And Company Antithrombotic agents
JP2000080085A (ja) 1997-09-01 2000-03-21 Kyorin Pharmaceut Co Ltd ６，７−非対称ジ置換キノキサリンカルボン酸誘導体とその付加塩及びそれらの製造方法
ATE312812T1 (de) 1999-02-22 2005-12-15 Pacific Corp Vanilloid-analoge die resiniferatoxin- pharmacophore enthalten als wirksame vanilloid rezeptor agonisten und analgetika, zusammensetzungen und ihre verwendung
DK1165516T3 (da) 1999-03-12 2005-01-31 Boehringer Ingelheim Pharma Heterocyklisk urinstof og beslægtede forbindelser, der er nyttige som antiinflammatoriske midler
AU1201401A (en) 1999-10-15 2001-04-30 Du Pont Pharmaceuticals Company Benzylcycloalkyl amines as modulators of chemokine receptor activity
CA2415606A1 (en) 2000-07-20 2002-01-31 Neurogen Corporation Capsaicin receptor ligands
WO2002016319A1 (en) 2000-08-21 2002-02-28 Pacific Corporation Novel thiourea compounds and the pharmaceutical compositions containing the same
AU2001278821A1 (en) 2000-08-21 2002-03-04 Pacific Corporation Novel thiocarbamic acid derivatives and the pharmaceutical compositions containing the same
JP5001505B2 (ja) 2000-08-21 2012-08-15 株式會社アモーレパシフィック 新規チオウレア誘導体およびこれを含有する薬学的組成物
JP2002080073A (ja) 2000-09-07 2002-03-19 Kyokuto Kobunshi Kk 電子レンジ用自動開孔袋
JP2002088073A (ja) * 2000-09-08 2002-03-27 Yamanouchi Pharmaceut Co Ltd 抗アンドロゲン剤
GB0110901D0 (en) 2001-05-02 2001-06-27 Smithkline Beecham Plc Novel Compounds
MY138086A (en) 2001-09-13 2009-04-30 Smithkline Beecham Plc Novel urea derivative as vanilloid receptor-1 antagonist
MXPA05000081A (es) * 2002-06-27 2005-04-11 Schering Ag Quinolinas sustituidas antagonistas del receptor ccr5.
WO2004024710A1 (en) * 2002-09-13 2004-03-25 Glaxo Group Limited Urea compounds active as vanilloid receptor antagonists for the treatment of pain
GB0229808D0 (en) 2002-12-20 2003-01-29 Glaxo Group Ltd Novel compositions
EP1740557A1 (en) 2004-04-20 2007-01-10 Bayer HealthCare AG Urea derivatives as antagonists of the vanilloid receptor (vr1)

Also Published As

Publication number Publication date
IL160755A0 (en) 2004-08-31
JP2005504074A (ja) 2005-02-10
WO2003022809A2 (en) 2003-03-20
CA2458632C (en) 2011-08-23
EP1425277B1 (en) 2009-01-07
PL213639B1 (pl) 2013-04-30
NO20041003L (no) 2004-06-04
EP2036902A2 (en) 2009-03-18
KR20090026369A (ko) 2009-03-12
NO327009B1 (no) 2009-04-06
JP4463552B2 (ja) 2010-05-19
WO2003022809A3 (en) 2003-07-17
OA12659A (en) 2006-06-19
HK1066534A1 (en) 2005-03-24
NO20085077L (no) 2004-06-04
PE20030417A1 (es) 2003-08-06
EP2298757A3 (en) 2011-12-28
KR20100082390A (ko) 2010-07-16
AP2004002982A0 (en) 2004-03-31
EA007731B1 (ru) 2006-12-29
MXPA04002379A (es) 2004-05-31
AU2002329397B2 (en) 2006-04-27
KR100955967B1 (ko) 2010-05-04
EP2036902A3 (en) 2009-05-06
NZ531137A (en) 2006-08-31
AP1818A (en) 2008-01-07
JP2010100632A (ja) 2010-05-06
CN1247568C (zh) 2006-03-29
TWI283665B (en) 2007-07-11
CA2458632A1 (en) 2003-03-20
KR20040041610A (ko) 2004-05-17
EP1425277B8 (en) 2009-04-01
EP1425277A2 (en) 2004-06-09
NO20085078L (no) 2004-06-04
CY1109449T1 (el) 2014-08-13
HUP0401923A2 (hu) 2005-01-28
EA200400432A1 (ru) 2004-12-30
AR038786A1 (es) 2005-01-26
UY27446A1 (es) 2003-04-30
EP2298757A2 (en) 2011-03-23
BR0212468A (pt) 2004-10-19
IL160755A (en) 2009-09-01
MA26216A1 (fr) 2004-07-01
MY138086A (en) 2009-04-30
KR101063679B1 (ko) 2011-09-07
CN1553905A (zh) 2004-12-08
PT1425277E (pt) 2009-03-05
US20090163506A1 (en) 2009-06-25
US8063078B2 (en) 2011-11-22
HUP0401923A3 (en) 2012-09-28
ES2316607T3 (es) 2009-04-16
PL369026A1 (en) 2005-04-18
ATE420083T1 (de) 2009-01-15
DE60230773D1 (de) 2009-02-26
SI1425277T1 (sl) 2009-04-30

Similar Documents

Publication Publication Date Title
DK1425277T3 (da) Urinstof-forbindelser aktive som vanilloid-receptor-antagonister til behandling af smerte
AU2003270199A1 (en) Urea compounds active as vanilloid receptor antagonists for the treatment of pain
DK1208095T3 (da) Dibenzopyraner som glucocorticoidreceptorantagonister til behandling af diabetes
NO20034122L (no) Sammensmeltede pyridinderivater for anvendelse som vanilloidreseptorantagonister for behandling av smerte
DK1505974T3 (da) Anvendelse af forbindelser, der er effektive som selektive opiatreceptormodulatorer
DK1485127T3 (da) Anvendelse af midler til behandling af inflammation
DK1339335T3 (da) Indretning til fiksering af knogler, især af hvirvellegemer i forhold til hinanden
DE60325025D1 (de) Modulatoren des vanilloidrezeptors
NO20041339L (no) Spiro-hydantoin-forbindelser anvendelige som anti-inflammatoriske midler
DK1339678T3 (da) Selektive agonister til EP4-receptor til behandling af osteoporose
ATE533743T1 (de) Harnstoffderivate von aminotetralin als modulatoren des vanilloid-rezeptors vr1
NO20032861D0 (no) Heteroarylurea nevropeptid YY5-reseptorantagonister
DE60317967D1 (de) Umhüllte feste Darreichungsform
NO20055238D0 (no) Kondenserte N-heterocykliske forbindelser og deres anvendelse som CRF-reseptorantagonister
DE50309032D1 (de) Fungizide wirkstoffkombinationen
DK2289514T5 (da) Pramipexol-doseringsform til anvendelse én gang dagligt
NO20030471D0 (no) Karboksamidforbindelser og deres anvendelse som antagonister for en 11CBY-reseptor
DK1862458T3 (da) Terapeutiske midler anvendelige til smertebehandling
DK1803718T3 (da) 4-Tetrazolyl-4-phenylpiperidin-derivater til behandling af smerter
DK1282616T3 (da) Hydroxyphenylpiperidin-4-ylidenmethylbenzamidderivater til behandling af smerter
DK1501806T3 (da) Præparater til topisk applikation af antiandrogent virksomme substanser
DE50213466D1 (de) Fungizide wirkstoffkombinationen
ATE492535T1 (de) 4-piperidinylalkylamin-derivate, antagonisten von muscarinrezeptoren
DE60224221D1 (de) Aminotetralinderivate, antagonisten von muscarinrezeptoren
NO20044373L (no) Azetidinderivater som CCR-3-reseptorantagonister